CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Serodus AS is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Serodus AS
Heia 8
Phone: +47 22958191p:+47 22958191 OSLO, 0268  Norway Ticker: 0QEX0QEX
Business Summary
Serodus AS is a Norway-based mid-stage clinical company. It is focused on treatments for patients with diabetic kidney disease. The Company has a dedicated focus on the treatment of patients with T2D and diabetic kidney disease and has a broad, chemically diversified basket of compounds. Serodus’s goal is to mature its SER150 candidate and subsequently enter partnerships for the remaining development, regulatory market approvals and global marketing. SER150 significantly reduced the key biomarker of kidney disease, albumin (protein) in urine, after only four weeks of treatment in patients with varying initial amounts of albumin in urine. SER150 was well tolerated, and no safety concerns were observed. The Company has two wholly owned subsidiaries, Serodus ApS (renamed from Phlogo) in Copenhagen, Denmark, and Serodus (AUS) Pty Ltd in Melbourne, Australia.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board SoerenElmann Ingerslev 1/1/2023 7/8/2013
Chief Executive Officer EvaSteiness 5/21/2014
Chief Financial Officer HenrikMordhorst 1/1/2019
Director Ole P.Nordby 62 7/8/2013 7/8/2013
Director Terri B.Sebree 65 4/24/2014 4/24/2014

Business Names
Business Name
0QEX
SER

General Information
Number of Employees: 2 (As of 9/30/2024)
Outstanding Shares: 44,502,062 (As of 9/30/2016)
Stock Exchange: OSL
Fax Number: +47 22604427


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024